Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and clinical relevance: Bewertung und klinische Relevanz;Pharmakokinetische Arzneimittelinteraktionen durch pflanzliche Arzneimittel

Wiener Medizinische Wochenschrift

Volumn 160, Issue 21-22, 2010, Pages 571-577

  Unger, Matthias ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cytochrome P450 enzymes; Drug interactions; Herbal drugs; P glycoprotein; St John's wort

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALPRAZOLAM; CAFFEINE; CYCLOSPORIN A; CYTOCHROME P450; DIGOXIN; DRUG METABOLITE; ECHINACEA EXTRACT; GINKGO BILOBA EXTRACT; GLICLAZIDE; GLYCOPROTEIN P; HERBACEOUS AGENT; HYPERICUM BUYERS CLUB; HYPERICUM PERFORATUM EXTRACT; IRINOTECAN; OMEPRAZOLE; SIMVASTATIN; TACROLIMUS; THEOPHYLLINE; TOLBUTAMIDE; TRUNATURE; UNCLASSIFIED DRUG; VALERIAN; CYP2C9 PROTEIN, HUMAN; LOSARTAN; PLANT EXTRACT; UNSPECIFIC MONOOXYGENASE;

AREA UNDER THE CURVE; ARTICLE; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG SCREENING; ECHINACEA; ENZYME SUBSTRATE; GINKGO BILOBA; HERB DRUG INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; BIOAVAILABILITY; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME INDUCTION; HYPERICUM; METABOLISM; PHYSIOLOGY; PHYTOTHERAPY; REVIEW; SILYBUM MARIANUM;

ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; LOSARTAN; MILK THISTLE; P-GLYCOPROTEIN; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 78651388913     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0848-4     Document Type: Article

References (31)

1. LZ Benet 2009 The drug transporter-metabolism alliance: uncovering and defining the interplay Mol Pharm 6 1631 1643 1:CAS:528:DC%2BD1MXhtlyhtL7J 10.1021/mp900253n 19874004
2. R Nowack J Andrassy M Fischereder, et al. 2009 Effects of dietary factors on drug transport and metabolism: the impact on dosage guidelines in transplant patients Clin Pharmacol Ther 85 439 443 1:CAS:528:DC%2BD1MXjtlSmurk%3D 10.1038/clpt.2008.303 19225452
3. M Unger 2004 Wie Naturstoffe die Bioverfügbarkeit von Phytopharmaka beeinflussen Pharm Ztg 149 979 986
4. V Schulz 2004 Arzneimittelinteraktionen: Relevanz für Phytopharmaka Z Phytotherapie 25 283 288
5. M Karliova U Treichel M Malagò, et al. 2000 Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation J Hepatol 33 853 855 1:STN:280: DC%2BD3Mzgtleqtw%3D%3D 10.1016/S0168-8278(00)80321-9 11097498
6. L Henderson OY Yue C Bergquist, et al. 2002 St. John's wort (Hypericum perforatum): drug interactions and clinical outcomes Br J Clin Pharmacol 54 349 356 1:CAS:528:DC%2BD38XpsVWit7g%3D 10.1046/j.1365-2125.2002.01683.x 12392581
7. E Mills VM Montori P Wu, et al. 2004 Interaction of St. John's wort with conventional drugs: systematic review of clinical trials BMJ 329 27 30 10.1136/bmj.329.7456.27 15231618
8. RS Obach 2000 Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression J Pharmacol Exp Ther 294 88 89 1:CAS:528:DC%2BD3cXksFyht7s%3D 10871299
9. R Madabushi B Frank B Drewelow, et al. 2006 Hyperforin in St. John's wort drug interactions Eur J Clin Pharmacol 62 225 233 1:CAS:528: DC%2BD28XitFOgs7o%3D 10.1007/s00228-006-0096-0 16477470
10. A Johne J Brockmöller S Bauer, et al. 1999 Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum) Clin Pharmacol Ther 66 338 345 1:CAS:528:DyaK1MXntlWiu7o%3D 10.1053/cp.1999.v66.a101944 10546917
11. K Sugimoto M Ohmori S Tsuruoka, et al. 2001 Different effects of St. John's wort on the pharmacokinetics of simvastatin and pravastatin Clin Pharmacol Ther 70 518 524 1:CAS:528:DC%2BD38XmtVCkuw%3D%3D 10.1067/mcp.2001. 120025 11753267
12. LS Wang G Zhou B Zhu, et al. 2004 St. John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole Clin Pharmacol Ther 75 191 197 1:CAS:528:DC%2BD2cXhslenurs%3D 10.1016/j.clpt.2003.09.014 15001970
13. S Bauer E Störmer A Johne, et al. 2003 Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients Br J Clin Pharmacol 55 203 211 1:CAS:528: DC%2BD3sXhvVyqs7g%3D 10.1046/j.1365-2125.2003.01759.x 12580993
14. I Mai E Störmer S Bauer, et al. 2003 Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients Nephrol Dial Transpl 18 819 822 1:CAS:528: DC%2BD3sXit1yqs78%3D 10.1093/ndt/gfg002
15. T Morimoto T Kotegawa K Tsutsumi, et al. 2004 Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers J Clin Pharmacol 44 95 101 1:CAS:528:DC%2BD2cXls1Ojug%3D%3D 10.1177/0091270003261496 14681347
16. H Xu KM Williams WS Liauw, et al. 2008 Effects of St. John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide Br J Pharmacol 153 1579 1586 1:CAS:528:DC%2BD1cXktVWms74%3D 10.1038/sj.bjp.0707685 18204476
17. G Arold F Donath A Maurer, et al. 2005 No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John's wort extract Planta Med 71 331 337 1:CAS:528:DC%2BD2MXksFKrsbs%3D 10.1055/s-2005-864099 15856409
18. RH Mathijssen J Verweij P de Bruijn, et al. 2002 Effects of St. John's wort on irinotecan metabolism J Natl Cancer I 94 1247 1249 1:CAS:528: DC%2BD38XntVyjsL8%3D
19. R Tankanow HR Tamer DS Streetman, et al. 2003 Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha) J Clin Pharmacol 43 637 642 1:CAS:528:DC%2BD3sXkslGhsbo%3D 12817526
20. BJ Gurley SF Gardner MA Hubbard, et al. 2004 In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto Clin Pharmacol Ther 76 428 440 10.1016/j.clpt.2004.07.007 15536458
21. JL Donovan CL DeVane KD Chavin, et al. 2004 Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers Drug Metab Dispos 32 1333 1336 1:CAS:528:DC%2BD2cXhtFGitrfN 10.1124/dmd.104.001164 15328251
22. BJ Gurley SF Gardner MA Hubbard, et al. 2005 In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes Clin Pharmacol Ther 77 415 426 1:CAS:528:DC%2BD2MXktFCrtLY%3D 10.1016/j.clpt.2005.01.009 15900287
23. U Fuhr S Beckmann-Knopp A Jetter, et al. 2007 The effect of silymarin on oral nifedipine pharmacokinetics Planta Med 73 1429 1435 1:CAS:528: DC%2BD2sXhsVektr7L 10.1055/s-2007-990256 17968815
24. C Sridar TC Goosen UM Kent, et al. 2004 Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases Drug Metab Dispos 32 587 594 1:CAS:528:DC%2BD2cXktlOgtrw%3D 10.1124/dmd.32.6.587 15155549
25. NP Van Erp SD Baker M Zhao, et al. 2005 Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan Clin Cancer Res 11 7800 7806 1:CAS:528:DC%2BD2MXhtF2isL7F 10.1158/1078-0432.CCR-05-1288 16278402
26. RA Stearns PK Chakravarty R Chen, et al. 1995 Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P450 2C and 3A subfamily members Drug Metab Dispos 23 207 215 1:CAS:528:DyaK2MXjslWqtrY%3D 7736913
27. Y Han D Guo Y Chen, et al. 2009 Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers Eur J Clin Pharmacol 65 585 591 1:CAS:528:DC%2BD1MXntVSktLY%3D 10.1007/s00228-009-0624-9 19221727
28. LL Von Moltke JL Weemhoff E Bedir, et al. 2004 Inhibition of human cytochromes P450 by components of Ginkgo biloba J Pharm Pharmacol 56 1039 1044 1:CAS:528:DC%2BD2cXntFeisbc%3D 10.1211/0022357044021 15285849
29. DJ Greenblatt LL von Moltke Y Luo, et al. 2006 Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate J Clin Pharmacol 46 214 221 1:CAS:528:DC%2BD28XhsFejsLk%3D 10.1177/0091270005283465 16432273
30. BJ Gurley SF Gardner MA Hubbard, et al. 2005 Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St. John's wort, garlic oil, Panax ginseng and Ginkgo biloba Drugs Aging 22 525 539 1:CAS:528:DC%2BD2MXpsFGmsb4%3D 10.2165/00002512-200522060-00006 15974642
31. HP Lei G Wang LS Wang, et al. 2009 Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers Ann Pharmacother 43 726 731 1:CAS:528: DC%2BD1MXltFequ7Y%3D 10.1345/aph.1L537 19299322